Comparative Pharmacology
Head-to-head clinical analysis: H CORT versus HYDROCORTISONE SODIUM SUCCINATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: H CORT versus HYDROCORTISONE SODIUM SUCCINATE.
H-CORT vs HYDROCORTISONE SODIUM SUCCINATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
H-CORT (hydrocortisone) is a corticosteroid with glucocorticoid and mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Hydrocortisone sodium succinate is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory, immunosuppressive, and anti-stress responses. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Intravenous: 100-250 mg as a single dose or up to 1 gram daily for acute conditions. Oral: 20-30 mg daily in divided doses. Maintenance: 5-20 mg daily.
100–500 mg IV or IM every 2–6 hours, as needed; typical initial dose 100–250 mg IV bolus followed by 100–250 mg IV every 4–6 hours for acute conditions.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours. Clinical context: Short half-life requires q4-6h dosing; duration may be prolonged in hepatic impairment.
1.5-2 hours (plasma terminal); biological half-life 8-12 hours (due to intracellular effects), requiring q6-8h dosing in adrenal insufficiency
Renal: ~80% as metabolites, ~5% unchanged; biliary/fecal: ~15%
Renal (90-95% as metabolites, <5% unchanged); biliary/fecal <5%
Category C
Category D/X
Corticosteroid
Corticosteroid